<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600258</url>
  </required_header>
  <id_info>
    <org_study_id>DeniseMafra10</org_study_id>
    <nct_id>NCT04600258</nct_id>
  </id_info>
  <brief_title>Chocolate for Patients With Chronic Kidney Disease</brief_title>
  <official_title>Chocolate for the Patient With Chronic Kidney Disease: a New Strategy to Modulate Inflammation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal Fluminense</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chocolate is a widely appreciated foodstuff with historical appreciation as food from the&#xD;
      gods. It is a rich source of (poly)phenolics, which have several proposed salutogenic&#xD;
      effects, including neuroprotective anti-inflammatory, antioxidant, and cardioprotective&#xD;
      properties.&#xD;
&#xD;
      This study will evaluate the potential salutogenic contribution of chocolate intake, to&#xD;
      mitigate inflammatory and oxidative burden in chronic kidney disease patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is evaluating patients with CKD on a regular HD program randomized in the&#xD;
      chocolate group and control group. The chocolate group is receiving 40g of dark chocolate per&#xD;
      day for 2 months and the control group is not receiving any intervention. Peripheral blood&#xD;
      mononuclear cells (PBMC) are being isolated for expression of Nrf2, NF-kB, and NADPH quinone&#xD;
      oxidoreductase 1 (NQO1) by a quantitative real-time polymerase chain reaction. Antioxidant&#xD;
      enzymes activity (catalase-CAT and glutathione peroxidase-GPx), high-sensitivity C-reactive&#xD;
      protein (hs-CRP) will be assessed using an enzyme-linked immunosorbent assay (ELISA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Chocolate group Control Group</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antioxidants and anti-inflammatory biomarkers</measure>
    <time_frame>2 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathioneperoxidase (GPx), heme oxygenase-1 (HO-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>2 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uremic toxins</measure>
    <time_frame>2 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects on uremic toxins plasma levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Chocolate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 40g dark chocolate per day, for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention and analysis will be performed before and after 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dark Chocolate</intervention_name>
    <description>The patients will receive 40g per day of dark chocolate for 2 months</description>
    <arm_group_label>Chocolate Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Chronic Kidney Disease&#xD;
&#xD;
          -  Hemodialysis patients for more than 6 months&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients pregnant&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Using antibiotics in the last 3 months&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Clinical diagnosis of infectious diseases&#xD;
&#xD;
          -  Clinical diagnosis of Cancer&#xD;
&#xD;
          -  Clinical diagnosis of AIDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Denise Mafra</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22260-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Mafra, phd</last_name>
      <phone>5521985683003</phone>
      <email>dmafra30@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Denise Mafra, PhD</last_name>
      <phone>+5521985683003</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Denise Mafra</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22260050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Mafra, phd</last_name>
      <phone>+5521985683003</phone>
      <email>dmafra30@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Fanton S, Cardozo LFMF, Combet E, Shiels PG, Stenvinkel P, Vieira IO, Narciso HR, Schmitz J, Mafra D. The sweet side of dark chocolate for chronic kidney disease patients. Clin Nutr. 2021 Jan;40(1):15-26. doi: 10.1016/j.clnu.2020.06.039. Epub 2020 Jul 14. Review.</citation>
    <PMID>32718711</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal Fluminense</investigator_affiliation>
    <investigator_full_name>Denise Mafra</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

